Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Mild cognitive impairment

Topic: Brain proteins, microglia and lab models

Plain-language summary

The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group. The CN and PD-MCI reversion groups did not significantly differ in any of the CSF markers. PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 430 participants. This longitudinal study found that people with Parkinson's disease and mild cognitive impairment who reverted to normal cognition had more favorable cerebrospinal fluid markers of Alzheimer's disease pathology than those who did not revert. It describes a prognostic difference and does not test any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ryczek, C. A., Rivas, R., Hemphill, L., Zanotelli, Z., Renteria, N., Dashtipour, K., et al. (2025). Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson’s Disease. Journal of Neuropsychiatry. https://doi.org/10.1176/appi.neuropsych.20240099

Vancouver

Ryczek CA, Rivas R, Hemphill L, Zanotelli Z, Renteria N, Dashtipour K, et al. Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson’s Disease. Journal of Neuropsychiatry. 2025. doi:10.1176/appi.neuropsych.20240099. PMID: 39789939.

BibTeX

@article{ryczek2025-39789939,
  author  = {Ryczek, Cameron A. and Rivas, Rhiannon and Hemphill, Lea and Zanotelli, Zackary and Renteria, Nicholas and Dashtipour, Khashayar and Jones, Jacob D.},
  title   = {{Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson’s Disease}},
  journal = {Journal of Neuropsychiatry},
  year    = {2025},
  doi     = {10.1176/appi.neuropsych.20240099},
  pmid    = {39789939},
  url     = {https://doi.org/10.1176/appi.neuropsych.20240099}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This longitudinal study found that people with Parkinson's disease and mild cognitive impairment who reverted to normal cognition had more favorable cerebrospinal fluid markers of Alzheimer's disease pathology than those who did not revert. It describes a prognostic difference and does not test any treatment, cure, or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Neuropsychiatry)
Journal's citation record 2 / 4 Journal of Neuropsychiatry: journal h-index 155 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 430 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jacob D. Jones: h-index 22 (OpenAlex, whole career)
Institution's track record 0 / 3 Loma Linda University: institution h-index 401 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39789939)
Free to read 2 / 2 Free to read
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →